Current Report Filing (8-k)
June 11 2021 - 4:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 11, 2021
JAGUAR HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-36714
|
|
46-2956775
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
200 Pine Street, Suite 400
San Francisco, California
|
|
94104
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (415) 371-8300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.0001 Per Share
|
JAGX
|
The Nasdaq Capital Market
|
On June 11, 2021, Jaguar
Health, Inc. (the “Company”) reconvened its 2021 Annual Meeting of Stockholders (the “Annual Meeting”)
that was adjourned on May 13, 2021. At the Annual Meeting, there continued to be an insufficient number of shares of the Company’s
common stock present or represented by proxy to constitute quorum. The Company adjourned the Annual Meeting until July 9, 2021 at
8:30 a.m. Pacific Time / 11:30 a.m. Eastern Time. At that time, the Annual Meeting will be reconvened at the Company’s
offices at 200 Pine Street, Suite 400, San Francisco, CA 94104.
The record date for the Annual
Meeting remains April 12, 2021. Stockholders of the Company who have previously submitted their proxy or otherwise voted and
who do not want to change their vote do not need to take any action.
No changes have been made
in the proposals to be voted on by stockholders at the Annual Meeting. The Company strongly encourages all of its stockholders to read
the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the “SEC”)
on April 13, 2021 (the “Proxy Statement”) and other proxy materials relating to the Annual Meeting, which are available
free of charge on the SEC’s website at www.sec.gov.
On June 11, 2021, the
Company issued a press release to announce the adjournment, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in any such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
JAGUAR HEALTH, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Lisa A. Conte
|
|
|
Name:
|
Lisa A. Conte
|
|
|
Title:
|
President and Chief Executive Officer
|
Date: June 11, 2021
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Apr 2024 to May 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From May 2023 to May 2024